MedTrace Logo

The Efficacy of Long-Chain Fatty Acids, Eicosapentaenoic Acid (EPA) and Specialized Pro-Resolving Mediators (SPMs), in Treating Long COVID Neuropsychiatric Symptoms

NCT07711444 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2026-07-21

No results posted yet for this study

Summary

Researchers conducted a 12-week, double-blind, randomized, placebo-controlled trial to assess the effectiveness of EPA or SPM treatments versus a placebo in managing Long COVID symptoms in adult patients. Researchers planned to enroll 240 eligible participants from various general and psychiatric hospitals in Taiwan. The focus was on evaluating the therapeutic impact and potential side effects of administering 3 g/day of EPA or 1.67 mg/day of SPMs on symptoms of depression in these patients. This consolidated approach aims to provide comprehensive insights into the efficacy of EPA and SPM treatments in Long COVID cases, addressing crucial mental health aspects.

Conditions

  • COVID - 19
  • Depression - Major Depressive Disorder

Interventions

DIETARY_SUPPLEMENT

Eicosapentaenoic acid (omega-3 fatty acid)

A total daily dose of 3 g, administered as six capsules

DIETARY_SUPPLEMENT

Specialized Pro-Resolving Lipid Mediator

A total daily dose of 1.67 g, administered as six capsules

DIETARY_SUPPLEMENT

Placebo

Six capsules containing soybean oil daily

Sponsors & Collaborators

  • National Science and Technology Council, Taiwan

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-01
Primary Completion
2025-12-01
Completion
2026-06-01

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07711444 on ClinicalTrials.gov